Ebola virus: from discovery to vaccine

Ebola virus, being highly pathogenic for humans and non-human primates and the subject of former weapons programmes, is now one of the most feared pathogens worldwide. In addition, the lack of pre- and post-exposure interventions makes the development of rapid diagnostics, new antiviral agents and protective vaccines a priority for many nations. Further insight into the ecology, immunology and pathogenesis of Ebola virus will promote the delivery of these urgently required tools.

[1]  H. Feldmann,et al.  Classification, structure, and replication of filoviruses. , 1999, Current topics in microbiology and immunology.

[2]  M. Bray,et al.  Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. , 2001, Journal of comparative pathology.

[3]  M. Bray,et al.  Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. , 2001, Journal of comparative pathology.

[4]  J. Wilson,et al.  Epitopes involved in antibody-mediated protection from Ebola virus. , 2000, Science.

[5]  S. R. Pattyn,et al.  Ebola virus haemorrhagic fever , 1978 .

[6]  H. Klenk,et al.  The asialoglycoprotein receptor is a potential liver-specific receptor for Marburg virus. , 1995, The Journal of general virology.

[7]  H. Feldmann,et al.  Marburg and Ebola viruses. , 1996, Advances in virus research.

[8]  C. Goldsmith,et al.  Pathologic features of filovirus infections in humans. , 1999, Current topics in microbiology and immunology.

[9]  A. Sanchez,et al.  Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. , 1998, Science.

[10]  J. Smith,et al.  Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. , 1998, Virology.

[11]  W. Slenczka,et al.  Zur Ätiologie einer unbekannten, von Affen ausgegangenen menschlichen Infektionskrankheit , 1967 .

[12]  P. Rollin,et al.  Markedly elevated levels of interferon (IFN)-γ, IFN-α, interleukin (IL)-2, IL-10, and tumor necrosis factor-α associated with fatal Ebola virus infection , 1999 .

[13]  Processing of the Ebola virus glycoprotein. , 1999, Current topics in microbiology and immunology.

[14]  D. Simpson,et al.  Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). , 1985, The Journal of infectious diseases.

[15]  M. Goldsmith,et al.  Folate Receptor-α Is a Cofactor for Cellular Entry by Marburg and Ebola Viruses , 2001, Cell.

[16]  V. Volchkov,et al.  [Immunobiological properties of vp24 protein of Ebola virus expressed by recombinant vaccinia virus]. , 1997, Voprosy virusologii.

[17]  G. Neild,et al.  Ultrastructural pathology of experimental ebola haemorrhagic fever virus infection , 1985, Journal of Pathology.

[18]  R. Ahmed,et al.  Passive Transfer of Antibodies Protects Immunocompetent and Immunodeficient Mice against Lethal Ebola Virus Infection without Complete Inhibition of Viral Replication , 2001, Journal of Virology.

[19]  S. Soong,et al.  Herpes zoster: risk categories for persistent pain. , 1999, The Journal of infectious diseases.

[20]  Shinji Watanabe,et al.  Identification of Protective Epitopes on Ebola Virus Glycoprotein at the Single Amino Acid Level by Using Recombinant Vesicular Stomatitis Viruses , 2003, Journal of Virology.

[21]  A. Sanchez,et al.  The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[22]  D. Simpson,et al.  Ebola virus: a comparison, at ultrastructural level, of the behaviour of the Sudan and Zaire strains in monkeys. , 1978, British journal of experimental pathology.

[23]  H. Feldmann,et al.  Infection and Activation of Monocytes by Marburg and Ebola Viruses , 2001, Journal of Virology.

[24]  D. Peters,et al.  [On the etiology of an unknown human infection originating from monkeys]. , 1967, Deutsche medizinische Wochenschrift.

[25]  Y. Kawaoka,et al.  Antibody-Dependent Enhancement of Ebola Virus Infection , 2003, Journal of Virology.

[26]  H. Klenk,et al.  Three of the Four Nucleocapsid Proteins of Marburg Virus, NP, VP35, and L, Are Sufficient To Mediate Replication and Transcription of Marburg Virus-Specific Monocistronic Minigenomes , 1998, Journal of Virology.

[27]  G. Martini,et al.  Marburg Virus Disease , 1971, Springer Berlin Heidelberg.

[28]  E. Ryabchikova,et al.  An analysis of features of pathogenesis in two animal models of Ebola virus infection. , 1999, The Journal of infectious diseases.

[29]  D. Simpson,et al.  Ebola haemorrhagic fever: experimental infection of monkeys. , 1978, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[30]  P. Bates,et al.  Characterization of Ebola Virus Entry by Using Pseudotyped Viruses: Identification of Receptor-Deficient Cell Lines , 1998, Journal of Virology.

[31]  Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. , 1978, Bulletin of the World Health Organization.

[32]  M. Georges-Courbot,et al.  Inflammatory responses in Ebola virus‐infected patients , 2002, Clinical and experimental immunology.

[33]  H. Feldmann,et al.  Biosynthesis and role of filoviral glycoproteins. , 2001, The Journal of general virology.

[34]  J. Leduc,et al.  An introduction to Ebola: the virus and the disease. , 1999, The Journal of infectious diseases.

[35]  G. Eddy,et al.  INACTIVATED VACCINE FOR EBOLA VIRUS EFFICACIOUS IN GUINEAPIG MODEL , 1980, The Lancet.

[36]  A. Sanchez,et al.  Development of a preventive vaccine for Ebola virus infection in primates , 2000, Nature.

[37]  Howard R. Petty,et al.  Ebola Virus Secretory Glycoprotein (sGP) Diminishes FcγRIIIB-to-CR3 Proximity on Neutrophils1 , 2000, The Journal of Immunology.

[38]  E. Ryabchikova,et al.  Animal pathology of filoviral infections. , 1999, Current topics in microbiology and immunology.

[39]  P. Jahrling,et al.  Pathology of experimental Ebola virus infection in African green monkeys. Involvement of fibroblastic reticular cells. , 1997, Archives of pathology & laboratory medicine.

[40]  P. Jahrling,et al.  DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. , 1998, Virology.

[41]  R. Heimark,et al.  Cadherin-5 redistribution at sites of TNF-α and IFN-γ-induced permeability in mesenteric venules. , 1999, American journal of physiology. Heart and circulatory physiology.

[42]  P. Jahrling,et al.  Apoptosis Induced In Vitro and In Vivo During Infection by Ebola and Marburg Viruses , 2000, Laboratory Investigation.

[43]  V. Volchkov,et al.  The Ebola virus VP35 protein functions as a type I IFN antagonist. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[44]  C. Boesch,et al.  Isolation and partial characterisation of a new strain of Ebola virus , 1995, The Lancet.

[45]  Stephan Becker,et al.  Comparison of the Transcription and Replication Strategies of Marburg Virus and Ebola Virus by Using Artificial Replication Systems , 1999, Journal of Virology.

[46]  G. Ignatyev,et al.  Immune response to filovirus infections. , 1999, Current topics in microbiology and immunology.

[47]  P. Debré,et al.  Human asymptomatic Ebola infection and strong inflammatory response , 2000, The Lancet.

[48]  Philip K. Russell,et al.  Hemorrhagic fever viruses as biological weapons: medical and public health management. , 2002, JAMA.

[49]  B. Pulendran,et al.  Cutting Edge: Impairment of Dendritic Cells and Adaptive Immunity by Ebola and Lassa Viruses1 , 2003, The Journal of Immunology.

[50]  M. Goldsmith,et al.  Differential induction of cellular detachment by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. , 2000, The Journal of general virology.

[51]  J. P. Chen,et al.  Hemorrhagic fever virus-induced changes in hemostasis and vascular biology , 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[52]  A. Rowe,et al.  Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. , 1999, The Journal of infectious diseases.

[53]  A. Sanchez,et al.  Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. , 2000, Vaccine.

[54]  R. Colebunders,et al.  Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. , 1999, The Journal of infectious diseases.

[55]  D. Burton,et al.  Pre- and Postexposure Prophylaxis of Ebola Virus Infection in an Animal Model by Passive Transfer of a Neutralizing Human Antibody , 2002, Journal of Virology.

[56]  V. Blinov,et al.  The envelope glycoprotein of Ebola virus contains an immunosuppressive‐like domain similar to oncogenic retroviruses , 1992, FEBS letters.

[57]  M. Bray.  The role of the Type I interferon response in the resistance of mice to filovirus infection. , 2001, The Journal of general virology.

[58]  P. Jahrling,et al.  Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections. , 2002, Virology.

[59]  Emiko Suzuki,et al.  Ebola Virus VP40 Drives the Formation of Virus-Like Filamentous Particles Along with GP , 2002, Journal of Virology.

[60]  V. Ternovoi,et al.  [Attempts to develop a vaccine against Ebola fever]. , 1995, Voprosy virusologii.

[61]  P. Debré,et al.  Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients , 1999, Nature Medicine.

[62]  P. Jahrling,et al.  Evaluation in Nonhuman Primates of Vaccines against Ebola Virus , 2002, Emerging infectious diseases.

[63]  M. K. Hart.  Vaccine research efforts for filoviruses. , 2003, International journal for parasitology.

[64]  P. Jahrling,et al.  Preliminary report: isolation of Ebola virus from monkeys imported to USA , 1990, The Lancet.

[65]  H. Feldmann,et al.  Viral hemorrhagic fever – a vascular disease? , 2003, Thrombosis and Haemostasis.

[66]  H. Feldmann,et al.  Molecular pathogenesis of filovirus infections: role of macrophages and endothelial cells. , 1999, Current topics in microbiology and immunology.

[67]  H. Takehara,et al.  Isolation of IgGT from hyperimmune horse anti-snake venom serum: its protective ability. , 1991, Toxicon.

[68]  J. Wilson,et al.  Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. , 2001, Virology.

[69]  Bas Huijbregts,et al.  Catastrophic ape decline in western equatorial Africa , 2003, Nature.

[70]  D R Burton,et al.  Recombinant human monoclonal antibodies to Ebola virus. , 1999, The Journal of infectious diseases.

[71]  P. Jahrling,et al.  Association of Ebola-related Reston virus particles and antigen with tissue lesions of monkeys imported to the United States. , 1992, Journal of comparative pathology.

[72]  Á. Corbí,et al.  C-Type Lectins DC-SIGN and L-SIGN Mediate Cellular Entry by Ebola Virus in cis and in trans , 2002, Journal of Virology.

[73]  E. Nabel,et al.  Immunization for Ebola virus infection , 1998, Nature Medicine.

[74]  P. Jahrling,et al.  Pathogenesis of experimental Ebola virus infection in guinea pigs. , 1999, The Journal of infectious diseases.

[75]  P. Jahrling,et al.  Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. , 1996, Archives of virology. Supplementum.

[76]  A. Sanchez,et al.  Ebola Virus Selectively Inhibits Responses to Interferons, but Not to Interleukin-1β, in Endothelial Cells , 1999, Journal of Virology.

[77]  Shinji Watanabe,et al.  Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry. , 2000, Virology.

[78]  J. McCormick,et al.  Experimental filovirus infections. , 1999, Current topics in microbiology and immunology.

[79]  Shinji Watanabe,et al.  Infectivity-Enhancing Antibodies to Ebola Virus Glycoprotein , 2001, Journal of Virology.

[80]  E. Nabel,et al.  Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury , 2000, Nature Medicine.

[81]  I. Borisevich,et al.  [The evaluation in hamadryas baboons of the possibility for the specific prevention of Ebola fever]. , 1994, Voprosy virusologii.

[82]  Shinji Watanabe,et al.  Reverse Genetics Demonstrates that Proteolytic Processing of the Ebola Virus Glycoprotein Is Not Essential for Replication in Cell Culture , 2002, Journal of Virology.

[83]  H. Feldmann,et al.  Release of viral glycoproteins during Ebola virus infection. , 1998, Virology.

[84]  D. Smith,et al.  A comparison of ovine and equine antivenoms. , 1994, Toxicon : official journal of the International Society on Toxinology.

[85]  Ignatyev Gm.  Immune response to filovirus infections. , 1999 .

[86]  M. Bray,et al.  A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. , 1998, The Journal of infectious diseases.

[87]  P Brès,et al.  [The epidemic of Ebola haemorrhagic fever in Sudan and Zaire, 1976: introductory note]. , 1978, Bulletin of the World Health Organization.

[88]  V. Volchkov,et al.  Recovery of Infectious Ebola Virus from Complementary DNA: RNA Editing of the GP Gene and Viral Cytotoxicity , 2001, Science.

[89]  D. Burton,et al.  Ebola Virus, Neutrophils, and Antibody Specificity , 1998 .

[90]  V. Volchkov,et al.  Molecular characterization of guinea pig-adapted variants of Ebola virus. , 2000, Virology.

[91]  H. Feldmann,et al.  Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages , 1996, Journal of virology.